- Email: [email protected]
OP-239 Impact of Number of Medications on Anticoagulation Control in Patients Receiving Warfarin Therapy
MARCH 13e16, 2014 Table 1 The treatment regimes in the table indicate the numbers at admission not the treatment strategy transitions.
cognitive disorder, postoperative NVAF, NVAF due to reversible causes, acute coronary syndromes or any operations within the last 3 months, who participated in another clinical trial in the last 6 months, and pregnant or breastfeeding women were excluded. Treatment regimes and clinical features were recorded. CHADS2, CHA2DS2-VASc, HAS-BLED scores and EQ-5D scale were used to assess risk factors and QoL. The interim analysis results are presented. Results: Of 213 patients, 57.3% were males (mean age, 64.2013.73 years) and 42.7% were females (mean age, 65.7411.65 years). The mean of CHADS2, CHA2DS2-VASc, and HAS-BLED scores were 1.571.08, 2.861.58, and 1.631.08, respectively. The distribution of the patients using warfarin, aspirin, aspirinþclopidogrel, other anti-thrombotic regimens (includes aspirinþwarfarin, warfarinþclopidogrel, and new oral anti-coagulant), and according to CHADS22 was 56.1% (n¼46), 64.3% (n¼18), 66.7% (n¼2), 41.7% (n¼5), and 31.8% (n¼14), respectively; whereas it was 84.1% (n¼69), 89.3% (n¼25), 100.0% (n¼3),100.0% (n¼12), and 65.9% (n¼29), respectively, according to CHA2DS2-VASc2. Moreover, this distribution was 20.7 (n¼17), 21.4% (n¼6), 0.0%, 33.3% (n¼4), and 9.1% (n¼4), respectively according to HAS-BLED3 (high bleeding risk). Conclusions: The stroke prevention strategy in NVAF may show a wide variation despite guidelines’ recommendations. The impacts on QoL of these treatment strategies are as much important as their efficacy and safety.
to examine the relationship between the number of medications prescribed alongside warfarin and anticoagulation control as measured by ‘International Normalized Ratio’ (INR). Methods: One-hundred and thirty-six patients (mean age 65.6 11.1 years) who had visited the outpatient cardiology clinic of a university hospital while receiving warfarin were investigated. Patients with cognitive or neurological deficits were excluded. Demographic and clinical data (including target INR range, and last 6 INR values) were collected. Good anticoagulation control (GAC) was defined as achieving target INR value in at least >¼60% of measurements. Patients were grouped according to number of medications that patients were taking every day; 1 to 3 medications (group 1, n ¼ 51), 4 to 5 medications (group 2, n ¼ 57), > 5 medications (group 3, n ¼ 28). Results: 63% of the patients received more than three pills every day. The majority of patients were female (n ¼ 87, 64%), and the most frequent warfarin indication was nonvalvular atrial fibrillation (n¼106, 78%). Most patients (66%) have been treated for at least 1 year. Only 41.9 % of participants had good anticoagulation control. Patients in group 1 were younger (p ¼ 0.003) compared to group 2 and 3 (Table 1). There was no significant difference for anticoagulation control between groups (P ¼ 0.261). There was no difference in the mean number of medications between good and poor anticoagulation control groups (4.3 1.7 vs. 4.1 1.7, P ¼ 0.640). Conclusion: In this patient cohort, contrary to popular belief, there was no relationship between the number of medication taken by patient and good anticoagulation control. It is obvious that anticoagulation control remains to be improved.
Table 1 Characteristics of patients
Stroke Risk and Prevention in Atrial Fibrillation Saturday, March 15, 2014 5:00 PM w 6:30 PM, Hall 6 (Abstract nos. OP-239 w OP-244) - OP-240 - OP-239 Impact of Number of Medications on Anticoagulation Control in Patients Receiving Warfarin Therapy. B. Kılıçkıran Avcı, _ E. Durmaz, E. Ertürk, B. Ikitimur, B. Karadag, V.A. Vural, Z. Öngen. Department of Cardiology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey. Objective: Patients on chronic warfarin therapy who have poor anticoagulation control are at increased risk for adverse events. Increasing regimen complexity is generally assumed to result in lower medication adherence, but there is conflicting evidence. The aim of this study was
Efficacy and Safety of Dabigatran Etexilate in Patients with Atrial Fibrillation: Short- term Results. Ö. Uz1, E. Erdal1, M. Dogan1, M. Atalay2, M. Yalçın1, Z. Is¸ılak1, M. Uzun1. 1Department of _ Cardiology, GATA Haydarpas¸a Training Hospital, Istanbul, Turkey; 2 Department of Cardiology, Merzifon Military Hospital, Amasya, Turkey. Objectives: The aim of this study was to evaluate the efficacy and safety of dabigatran etexilate in patients with nonvalvular atrial fibrillation (AF), after its post-approval availability in Turkey. Methods: From January 2013 to November 2013 totally 50 patients with the diagnosis of nonvalvular AF who were started to taking
The American Journal of Cardiologyâ MARCH 13e16, 2014 10th INTERNATIONAL CONGRESS OF UPDATE IN CARDIOLOGY AND CARDIOVASCULAR SURGERY ABSTRACTS / Oral
S51
O R A L A B S T R A C T S
cognitive disorder, postoperative NVAF, NVAF due to reversible causes, acute coronary syndromes or any operations within the last 3 months, who participated in another clinical trial in the last 6 months, and pregnant or breastfeeding women were excluded. Treatment regimes and clinical features were recorded. CHADS2, CHA2DS2-VASc, HAS-BLED scores and EQ-5D scale were used to assess risk factors and QoL. The interim analysis results are presented. Results: Of 213 patients, 57.3% were males (mean age, 64.2013.73 years) and 42.7% were females (mean age, 65.7411.65 years). The mean of CHADS2, CHA2DS2-VASc, and HAS-BLED scores were 1.571.08, 2.861.58, and 1.631.08, respectively. The distribution of the patients using warfarin, aspirin, aspirinþclopidogrel, other anti-thrombotic regimens (includes aspirinþwarfarin, warfarinþclopidogrel, and new oral anti-coagulant), and according to CHADS22 was 56.1% (n¼46), 64.3% (n¼18), 66.7% (n¼2), 41.7% (n¼5), and 31.8% (n¼14), respectively; whereas it was 84.1% (n¼69), 89.3% (n¼25), 100.0% (n¼3),100.0% (n¼12), and 65.9% (n¼29), respectively, according to CHA2DS2-VASc2. Moreover, this distribution was 20.7 (n¼17), 21.4% (n¼6), 0.0%, 33.3% (n¼4), and 9.1% (n¼4), respectively according to HAS-BLED3 (high bleeding risk). Conclusions: The stroke prevention strategy in NVAF may show a wide variation despite guidelines’ recommendations. The impacts on QoL of these treatment strategies are as much important as their efficacy and safety.
to examine the relationship between the number of medications prescribed alongside warfarin and anticoagulation control as measured by ‘International Normalized Ratio’ (INR). Methods: One-hundred and thirty-six patients (mean age 65.6 11.1 years) who had visited the outpatient cardiology clinic of a university hospital while receiving warfarin were investigated. Patients with cognitive or neurological deficits were excluded. Demographic and clinical data (including target INR range, and last 6 INR values) were collected. Good anticoagulation control (GAC) was defined as achieving target INR value in at least >¼60% of measurements. Patients were grouped according to number of medications that patients were taking every day; 1 to 3 medications (group 1, n ¼ 51), 4 to 5 medications (group 2, n ¼ 57), > 5 medications (group 3, n ¼ 28). Results: 63% of the patients received more than three pills every day. The majority of patients were female (n ¼ 87, 64%), and the most frequent warfarin indication was nonvalvular atrial fibrillation (n¼106, 78%). Most patients (66%) have been treated for at least 1 year. Only 41.9 % of participants had good anticoagulation control. Patients in group 1 were younger (p ¼ 0.003) compared to group 2 and 3 (Table 1). There was no significant difference for anticoagulation control between groups (P ¼ 0.261). There was no difference in the mean number of medications between good and poor anticoagulation control groups (4.3 1.7 vs. 4.1 1.7, P ¼ 0.640). Conclusion: In this patient cohort, contrary to popular belief, there was no relationship between the number of medication taken by patient and good anticoagulation control. It is obvious that anticoagulation control remains to be improved.
Table 1 Characteristics of patients
Stroke Risk and Prevention in Atrial Fibrillation Saturday, March 15, 2014 5:00 PM w 6:30 PM, Hall 6 (Abstract nos. OP-239 w OP-244) - OP-240 - OP-239 Impact of Number of Medications on Anticoagulation Control in Patients Receiving Warfarin Therapy. B. Kılıçkıran Avcı, _ E. Durmaz, E. Ertürk, B. Ikitimur, B. Karadag, V.A. Vural, Z. Öngen. Department of Cardiology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey. Objective: Patients on chronic warfarin therapy who have poor anticoagulation control are at increased risk for adverse events. Increasing regimen complexity is generally assumed to result in lower medication adherence, but there is conflicting evidence. The aim of this study was
Efficacy and Safety of Dabigatran Etexilate in Patients with Atrial Fibrillation: Short- term Results. Ö. Uz1, E. Erdal1, M. Dogan1, M. Atalay2, M. Yalçın1, Z. Is¸ılak1, M. Uzun1. 1Department of _ Cardiology, GATA Haydarpas¸a Training Hospital, Istanbul, Turkey; 2 Department of Cardiology, Merzifon Military Hospital, Amasya, Turkey. Objectives: The aim of this study was to evaluate the efficacy and safety of dabigatran etexilate in patients with nonvalvular atrial fibrillation (AF), after its post-approval availability in Turkey. Methods: From January 2013 to November 2013 totally 50 patients with the diagnosis of nonvalvular AF who were started to taking
The American Journal of Cardiologyâ MARCH 13e16, 2014 10th INTERNATIONAL CONGRESS OF UPDATE IN CARDIOLOGY AND CARDIOVASCULAR SURGERY ABSTRACTS / Oral
S51
O R A L A B S T R A C T S